## Drug of Choice for Post-MI Cardioprotection **Key Point:** Carvedilol is the preferred beta-blocker in post-MI patients due to its combined α- and β-blocking properties, which confer superior cardioprotective and mortality-reduction benefits. ### Mechanism of Carvedilol's Superiority 1. **Non-selective β-blockade** — reduces heart rate and contractility 2. **α1-blockade** — causes vasodilation, reducing afterload 3. **Antioxidant properties** — scavenges free radicals 4. **Anti-apoptotic effects** — reduces cardiomyocyte death ### Evidence Base The **COPERNICUS trial** (2001) demonstrated that carvedilol reduced mortality by ~35% in patients with severe left ventricular dysfunction post-MI, compared to placebo. This landmark study established carvedilol as the gold standard beta-blocker for post-MI heart failure. ### Comparison of Beta-Blockers in Post-MI Setting | Feature | Carvedilol | Metoprolol | Atenolol | Labetalol | | --- | --- | --- | --- | --- | | **β1-selectivity** | Non-selective | Selective | Selective | Non-selective | | **α-blockade** | Yes (strong) | No | No | Yes (moderate) | | **Antioxidant** | Yes | No | No | No | | **Mortality reduction (post-MI)** | +++ | ++ | ++ | + | | **Heart failure benefit** | Excellent | Good | Good | Fair | | **Lipid/glucose effects** | Neutral | Unfavorable | Unfavorable | Neutral | **High-Yield:** Carvedilol is the **only beta-blocker with proven mortality reduction in post-MI heart failure** and is recommended in all major guidelines (ACC/AHA, ESC) as first-line for this indication. **Clinical Pearl:** Carvedilol's vasodilatory α-blockade is particularly beneficial in post-MI patients who develop left ventricular remodeling and heart failure, as it reduces the compensatory vasoconstriction that occurs after MI. **Mnemonic:** **CAR**vedilol = **CAR**dioprotection + **A**ntioxidant + **R**emodeling prevention (in post-MI).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.